May 27, 2021: Recycling tenofovir in a second-line regimen; real-life two-drug regimen failure rates; jump-starting ART at sexual health clinics; viability of wearable devices in sleep assessment.
Four months after the approval of cabotegravir/rilpivirine, medical providers still face some tough questions about who might best benefit and how the medication might be covered.
May 6, 2021: Epigenetic aging and HIV treatment initiation; effects of ART on cognitive decline; dearth of osteoporosis screenings for PLWH; physical therapy vs. opioids for bone/muscle pain.
The latest update to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV occurred within the pediatric HIV prevention guidelines on April 8.
April 29, 2021: Measuring HIV drug susceptibility amidst extensive resistance; the reversibility of virologic failure; mobile HIV care in urban settings; whether to prescribe long-acting antiretroviral therapy.
In sub-Saharan Africa, herbalists and spiritual healers are working closely with researchers to help reduce HIV transmission in rural communities.
Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.
A recent analysis conducted by the AIDS Treatment Activists Coalition revealed that, among HIV drug trial participants, data specific to race and sex were dramatically underreported.
While findings from the high-profile AMP studies have excited scientists, they’re only one of a wide range of bNAb avenues currently being pursued.
Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.